EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer's Disease.

EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. Version 3 Description The EUREMAP project aims to optimise the marine bioprospecting workflow within the European research community, enabling state-of-the-art research and enhanced capacity for academia and industry. This will be achieved by building upon the existing expertise available within the consortium members (EU OPENSCREEN, EMBL, EMBRC, ELIXIR) to synergise capacities and resources to enhance marine bioprospecting for natural products. The EUREMAP platform to be developed will consist of a new multidisciplinary marine bioprospecting workflow that integrates the existing technical capacities, thereby increasing the competitiveness of marine natural products in drug discovery and strengthening the blue bioeconomy in line with the European blue growth strategy. The functioning EUREMAP marine bioprospecting workflow will support the discovery of novel bioactive natural products from marine organisms by utilising novel technology to improve the capacity of European Research infrastructures (RIs). The multidisciplinary nature of the marine bioprospecting research space necessarily requires integrating data flows between disparate research fields. As such, while data management components within disciplines may be in place, they may not be adequately formulated to provide the basis for a cohesive and integrated data workflow. The following dataset descriptions are specific to the EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BY-SA-4.0 DOI: - 19/11/2025 The project focuses on identifying and characterizing additional streptocyclinones present in the cultures of the marine Streptomyces sp. CA-237351. Known members of the streptocyclinone family have anti-inflammatory and neuroprotective properties). We aim to deepen the understanding of their biosynthesis and potential therapeutic applications and expand the known diversity of streptocyclinone variants. Funder Grant European Commission||EC European Research Infrastructure for Marine Bioprospecting (corda_____he::101131663) Researchers Stéphane Bach (0000-0002-7186-7483), Marcelino Suzuki (00000003-3868-6362), Fernando Reyes (0000-0003-1607-5106), Olga Genilloud (0000-0002-4202-1219), Jose Santiago Sanchez Fragoso (0000-0001-7018-3891) Organizations Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, SORBONNE Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 UNIVERSITE, European Molecular Biology Laboratory, Centre National de la Recherche Scientifique (CNRS), Paris Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 1. Main Info Title of DMP: EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. Description: The EUREMAP project aims to optimise the marine bioprospecting workflow within the European research community, enabling state-of-the-art research and enhanced capacity for academia and industry. This will be achieved by building upon the existing expertise available within the consortium members (EU OPENSCREEN, EMBL, EMBRC, ELIXIR) to synergise capacities and resources to enhance marine bioprospecting for natural products. The EUREMAP platform to be developed will consist of a new multidisciplinary marine bioprospecting workflow that integrates the existing technical capacities, thereby increasing the competitiveness of marine natural products in drug discovery and strengthening the blue bioeconomy in line with the European blue growth strategy. The functioning EUREMAP marine bioprospecting workflow will support the discovery of novel bioactive natural products from marine organisms by utilising novel technology to improve the capacity of European Research infrastructures (RIs). The multidisciplinary nature of the marine bioprospecting research space necessarily requires integrating data flows between disparate research fields. As such, while data management components within disciplines may be in place, they may not be adequately formulated to provide the basis for a cohesive and integrated data workflow. The following dataset descriptions are specific to the EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. The project focuses on identifying and characterizing additional streptocyclinones present in the cultures of the marine Streptomyces sp. CA-237351. Known members of the streptocyclinone family have anti-inflammatory and neuroprotective properties). We aim to deepen the understanding of their biosynthesis and potential therapeutic applications and expand the known diversity of streptocyclinone variants. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Researchers: Stéphane Bach (0000-0002-7186-7483) Marcelino Suzuki (0000-0003-3868-6362) Fernando Reyes (0000-0003-1607-5106) Olga Genilloud (0000-0002-4202-1219) Jose Santiago Sanchez Fragoso (0000-0001-7018-3891) Organizations: Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía SORBONNE UNIVERSITE European Molecular Biology Laboratory Centre National de la Recherche Scientifique (CNRS), Paris Contact: Genilloud Olga ([email protected]) 2. Funding Funding organizations: European Commission||EC Grants: European Research Infrastructure for Marine Bioprospecting (corda_____he::101131663) Project: EUREMAP: European Research Infrastructure for Marine Bioprospecting 3. License License: CC-BY-SA-4.0 Access Rights: Public 4. Templates Descriptions Structural Elucidation: LC-MS LC/HRMS and LC/MS/MS data necessary to determine the molecular formula of the new compounds and key fragments to contribute to their structural elucidation. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Template: Horizon Europe Type: Dataset 1 Summary 1.1 Brief description of the described research output 1.1.1 What kind of research output are you describing? Research Data 1.1.2 Is it physical or digital? Digital 1.1.3 Are you generating or re-using it? New Reusing of existing data is not applicable to the context of this study. 1.1.4 What is the type of the described dataset? Experimental The dataset consists of primary and secondary mass spectrometry data generated from LC-MS and LC/MS/MS based experiments. Primary data includes raw m/z values, retention times, intensity values and mass spectra, while secondary data includes processed tabular data derived from the raw measurements. 1.1.5 What is its format? •Raw data: vendor-specific format converted to .mzML •Pre-processed data: feature/peak in tabular format (.csv), pre-processed structured data in SQLite format for relational queries, and pre-processed data for posterior storing and annotations in JSON format. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 •Metabolite ID data: annotated metabolite tables (.csv, SQLite, JSON); Spectral match data (if storing MS/MS matches; .mgf) •Quantitative data: processed intensity data, peak areas or relative abundances (.csv, SQLite, JSON) •Statistical Data: tabular, Json and SQLite, R script 1.1.6 What is its expected size? ~10–50 GB for a small scale study (up to 50 samples) 1.1.7 Why are you collecting/generating or re-using it? • To obtain information • To share information • To keep on record • To make informed decisions • To combine with other data •to obtain information: collection of mass spectrometry data to establish the molecular formula of new compounds •to share information: making the data available for the scientific community to foster collaboration and enable reaseachers to build upon existing datasets; allowing fellow reseachers to compare their findings with the shared data; to support metabolomics-driven advancements •to keep on record: to permit for long-term accessibility and compliance; to suppot future reanalysis & method development; to facilitate data traceability •to make informed decisions: to guide experimental design and hypothesis refinement, enhancing biological intepretation and clinical/inustrial applications; to optimize resource allocation •to combine with NMR data for the structural elucidation of compounds Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 1.1.8 What is its origin / provenance? Compounds belonging to the streptocyclinone structural class purified during the development of the project. Compounds will be originated from Biomass extracts having an ID through a process registered in a LIMS system available at the institution. Unique ID identifiers will be generated for each compound. 1.1.9 To whom might it be useful ('data utility')? • Researchers • Research communities • The public • Industry •Researchers and research communities to verify the identity of their compounds •Industry for the same purpose in an industrial set up. 2 Links Between Outputs 2.1 Publications 2.1.1 Does the described output support any scientific publication? No 2.1.2 Is there a data availability statement provided along with the publication? No 2.3 Software 2.3.1 Does the described output use or support any software? Yes Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3 FAIR Practices 3.1 Making data and other outputs findable, including provisions for metadata 3.1.1 Making data findable, including provisions for metadata 3.1.1.1 What type(s) of persistent identifier(s) are used for the described dataset / output? • Data identifiers • Researchers identifiers DOI ORCID Once deposited, data will be available through a DOI Assigned by the database 3.1.1.2 Will you provide metadata for the described dataset / output? Yes "MetaboLights adheres to MSI standards for metadata reporting and uses the ISA-tab format [6] to capture and study metadata, including the metabolites identified or annotated." ISA-Tab: The Investigation/Study/Assay (ISA) tab-delimited (TAB) format is a general purpose framework with which to collect and communicate complex metadata (i.e. sample characteristics, technologies used, type of measurements made) from 'omics-based' experiments employing a combination of technologies. 3.1.1.3 What type(s) of metadata? • Descriptive • Administrative 3.1.1.4 Do the metadata use standardised vocabularies? Yes 3.1.1.5 Please provide URL/Description of used vocabularies Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 7 Other Issues 7.1 Other 7.1.1 Do you make use of other procedures for data management? No Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Structural Elucidation: NMR 1D and 2D NMR data of natural products isolated from extracts of microbial sources Template: Horizon Europe Type: Dataset 1 Summary 1.1 Brief description of the described research output 1.1.1 What kind of research output are you describing? Research Data 1.1.2 Is it physical or digital? Digital 1.1.3 Are you generating or re-using it? New Data will be generated from compounds purified during the development of the project 1.1.4 What is the type of the described dataset? Experimental The data set consists of primary NMR data generated by the instrument Secondary data will include NMR tables and structures of the compounds 1.1.5 What is its format? Bruker specific format readable by commercial and free access tools for NMR data SMILES for structures Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 1.1.6 What is its expected size? About 80 Mb per compound 1.1.7 Why are you collecting/generating or re-using it? • To obtain information • To share information • To keep on record • To combine with other data To obtain information necessary to elucidate the structure of the molecules obtained during the development of the project. To share information useful to other researchers to verify the identity of the compounds isolated in their own research. To keep on record of compounds NMR spectra To combine with HRMS data to solve the structure of new compounds 1.1.8 What is its origin / provenance? Compounds belonging to the streptocyclinone structural class purified during the development of the project. Compounds will be originated from Biomass extracts having an ID through a process registered in a LIMS system available at the institution. Unique ID identifiers will be generated for each compound. 1.1.9 To whom might it be useful ('data utility')? • Researchers • Research communities • Industry Researchers and research communities to verify the identity of their compounds Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Industry for the same purpose in an industrial set up. 2 Links Between Outputs 2.1 Publications 2.1.1 Does the described output support any scientific publication? No 2.1.2 Is there a data availability statement provided along with the publication? No 2.3 Software 2.3.1 Does the described output use or support any software? Yes https://www.bruker.com/en/products-and-solutions/mr/nmr-software/ topspin.html 3 FAIR Practices 3.1 Making data and other outputs findable, including provisions for metadata 3.1.1 Making data findable, including provisions for metadata 3.1.1.1 What type(s) of persistent identifier(s) are used for the described dataset / output? • Data identifiers • Researchers identifiers DOI ORCID Once deposited, data will be available through a DOI Assigned by the database 3.1.1.2 Will you provide metadata for the described dataset / output? Yes Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Metadata will include name and structure of the compound, species of origin, and experimental conditions used in the acquisition of the NMR data. 3.1.1.3 What type(s) of metadata? • Descriptive • Administrative 3.1.1.4 Do the metadata use standardised vocabularies? Yes 3.1.1.5 Please provide URL/Description of used vocabularies https://np-mrd.org/ Those required by NP-MRD 3.1.1.6 Are the metadata searchable? Yes 3.1.1.7 How are searchable metadata provided? Metadata repository Metadata will be deposited in NP-MRD database which provides search capabilities 3.1.1.8 Are keywords provided in the metadata? No 3.1.1.9 Are metadata harvestable? Yes 3.2 Making data and other outputs openly accessible 3.2.1 Repository 3.2.1.1 In which repository will the dataset / output be deposited? NP-MRD https://np-mrd.org/ Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 The NP-MRD is a freely available cloud-based, user-friendly, FAIR electronic database. NP-MRD accepts NMR data and associated metadata from newly undertaken NP studies. The NP-MRD accepts raw (time domain data, processed spectra, assigned chemical shifts, J-couplings, RDCs, etc.), and metadata (structures, sources, methods, taxonomy, geospatial data, etc) from natural products ranging from purified substances to crude extracts, in all major solvents. The NP-MRD include NPs such as vitamins, minerals, and probiotics as well as small molecules derived from plants, fungi, bacteria, marine organisms, or animals. The NP-MRD accepts, converts, and stores all major vendor NMR formats and all major NMR data exchange formats from all common NMR experiments as well as new/uncommon NMR experiments or data sets. The NP-MRD have an intuitive user interface for spectra/structure deposition, retrieval, search, and analysis. Data deposition is fast (<5 min/per spectrum), easy and intuitive, and aided by online assignment and online spectra/structure visualization tools. Structure and assignment validation reports are generated within 5 minutes of deposition and value-added data reports are provided to users within 24 hrs of deposition, including highquality DFT calculations of chemical shifts for a deposited structure. Data integrity and data quality are ensured by extensive curation efforts and the use of an objective ranking scale for all deposited data. 3.2.1.2 Is the selected repository a trusted source? Yes • Follows repository standards • Details terms of use • Has an open access content policy • Supports retention • Provides Open Access content (free at the point of use) • Assigns PIDs 3.2.1.4 Add appropriate arrangements made with the repository(ies) where the described dataset will be deposited Agreement to the terms of use and submission as set out by NP-MRD Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.1.5 Does the repository(ies) assign datasets / outputs with persistent identifiers? Yes 3.2.1.6 Does the repository(ies) resolve the identifiers to a digital object? Yes 3.2.1.7 Does the repository support versioning? Yes 3.2.2 Data 3.2.2.1 What is the described dataset / output title? NMR data of compound ID (NP-MRD ID) 3.2.2.2 How is the dataset / output shared? Open The database is open to all researchers 3.2.2.5 Are there any methods or tools required to access the dataset / output? No 3.2.2.8 Is the described dataset / output supported by a data access committee? No 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends The dataset and associated metadata will be available (longterm) via the NPMRD repository once all the IP and publication issues have been solved Through registration in NP-MRD 3.2.2.10 Please specify how long after the project has ended the dataset / output will be made accessible for Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Datasets will be available forever through NP-MRD 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes Datasets will be open after an embargo period 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Yes 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? Yes Not relevant because data will be stored in a permanent repository 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes Vocabulary required by NP-MRD 3.3.3 Have you applied a standard schema for your (meta)data? Yes Couldn't find it? Insert it manually Standard required by NP-MRD 3.3.7 Does the described dataset / output provide qualified references with other outputs? No Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? Creative Commons Attribution 4.0 After IP or publication issues have been solved 3.4.2 What reusability and / or reproducibility methods are followed? Other Instructions from NP-MRD 3.4.3 Will you provide the described dataset / output in the public domain? Yes 3.4.4 Do you intend to ensure (re)use by third parties after your project finishes? Yes The NP-MRD is open 3.4.5 Is provenance well documented? Yes Data will be originated from LIMS and lab notebooks. Biosamples ID 3.4.6 What documented procedures for quality assurance do you have in place? Data conform to format specification Data need to be uploaded to the database in a standard format 4 Allocation of Resources 4.1 Allocation of resources 4.1.1 What will be the cost of making the described output FAIR? 0 Euro • Storage Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 • Archiving • Re-use Indirect cost Use of MEDINA infrastructure, considered an in kind contribution 4.1.2 How will this cost be covered? • Use of institution infrastructure • Other In kind contribution 4.1.3 Identify the people who will be responsible and their role(s) in the management of the described output Francisco Javier Ortiz-Lopez, Senior Researcher, ORCID: 0000-0002-9410-3718 Fernando Reyes, Head of Chemistry, ORCID: 0000-0003-1607-5106 5 Security 5.1 Data Security 5.1.1 What security measures are followed? • Firewall • Passwords 5.1.2 What conditions do the security measures meet? • Data access • Data storage • Data transmission • Data recovery • Data sharing 5.1.3 How will you preserve the described dataset / output in the long term? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.2.8 Is the described dataset / output supported by a data access committee? No 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends The dataset will be shared internally, and deposited in BioStudies EMBL-EBI repository. 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Yes 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? Yes 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes Ecosystem classification - https://gold.jgi.doe.gov/ecosystem_classification 3.3.3 Have you applied a standard schema for your (meta)data? No 3.3.4 Will you provide a mapping to more commonly used ontologies? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 No 3.3.7 Does the described dataset / output provide qualified references with other outputs? No 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? An embargo period applies, the dataset will be made publicly available either upon the publication of a related paper or after a maximum period of three years, whichever comes first. 3.4.4 Do you intend to ensure (re)use by third parties after your project finishes? No Depends on outcomes 3.4.5 Is provenance well documented? Yes 3.4.6 What documented procedures for quality assurance do you have in place? Other QC after data entry. Perform statistical summaries. 4 Allocation of Resources 4.1 Allocation of resources 4.1.1 What will be the cost of making the described output FAIR? 5000 Euro • Storage • Archiving • Re-use Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 • Security Indirect cost 4.1.2 How will this cost be covered? Use of institution infrastructure 4.1.3 Identify the people who will be responsible and their role(s) in the management of the described output Jose Santiago Sanchez Fragoso (0000-0001-7018-3891) 5 Security 5.1 Data Security 5.1.1 What security measures are followed? • Firewall • Passwords • Hash functions 5.1.2 What conditions do the security measures meet? • Data access • Data storage • Data transmission • Data recovery • Data sharing 6 Ethical Aspects 6.1 Ethical aspects 6.1.1 Are there any ethical or legal issues that can have an impact on sharing the described dataset / output? unknown 6.1.2 Does the described dataset / output contain sensitive information? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Unknown 6.1.3 Does the described dataset / output contain personal data? No 7 Other Issues 7.1 Other 7.1.1 Do you make use of other procedures for data management? No Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Biomass production: A list of biomass samples from marine Streptomyces sp. CA-237351 with production conditions The data in this section refers to a table containing all individual biomass samples from fermentations (Growth in bioreactors) of the marine Streptomyces sp. CA-237351, including metadata on the conditions used for this production Template: Horizon Europe Type: Dataset 1 Summary 1.1 Brief description of the described research output 1.1.1 What kind of research output are you describing? Research Data 1.1.2 Is it physical or digital? Digital 1.1.3 Are you generating or re-using it? New this will be results of an ongoing demonstration project 1.1.4 What is the type of the described dataset? Experimental results of growth of Streptomyces sp. CA-237351 under diferent conditions 1.1.5 What is its format? a TSV file that could be used as a table in a relational database. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 1.1.6 What is its expected size? 1 MB 1.1.7 Why are you collecting/generating or re-using it? • To obtain information • To share information • To keep on record • To make informed decisions • To develop a product • To combine with other data This data will allow us in the end of the demonstration projet to identify and share the best production conditions for specific streptocyclinones that have a potential to be used as drug down the line 1.1.8 What is its origin / provenance? The data in the table will be weights in grams of dry or lyophilized material from bacterial cultures in bioreactors 1.1.9 To whom might it be useful ('data utility')? • Researchers • Industry The identification of conditions maximizing yields of production will be of interests for researchers looking for new molecules as well as industry in case these molecules become products 2 Links Between Outputs 2.1 Publications 2.1.1 Does the described output support any scientific publication? No 2.1.2 Is there a data availability statement provided along with the publication? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 No 2.3 Software 2.3.1 Does the described output use or support any software? No 3 FAIR Practices 3.1 Making data and other outputs findable, including provisions for metadata 3.1.1 Making data findable, including provisions for metadata 3.1.1.1 What type(s) of persistent identifier(s) are used for the described dataset / output? Projects identifiers URL Cordis this will be one of the deliverables of WP4 3.1.1.2 Will you provide metadata for the described dataset / output? No 3.1.1.5 Please provide URL/Description of used vocabularies https://pmc.ncbi.nlm.nih.gov/articles/PMC9265904/ A specific vocabulary has not been created, a similar one is mentioned in the like above or https://bioportal.bioontology.org/ontologies/SBO 3.2 Making data and other outputs openly accessible 3.2.1 Repository 3.2.1.1 In which repository will the dataset / output be deposited? BioStudies Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 https://www.ebi.ac.uk/biostudies/ The BioStudies database holds descriptions of biological studies, links to data from these studies in other databases at EMBL-EBI or outside, as well as data that do not fit in the structured archives at EMBL-EBI. The database can accept a wide range of types of studies described via a simple format. It also enables manuscript authors to submit supplementary information and link to it from the publication. 3.2.1.2 Is the selected repository a trusted source? Yes 3.2.2 Data 3.2.2.1 What is the described dataset / output title? Euremap Streptomyces Demonstration Project Biomass Production 3.2.2.2 How is the dataset / output shared? Closed 3.2.2.3 What is the reason of limiting access to the dataset / output? The possibility of industrialization of the results 3.2.2.5 Are there any methods or tools required to access the dataset / output? No 3.2.2.8 Is the described dataset / output supported by a data access committee? No 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends We will share it to the sharepoint of the Project Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes The sample metadata will be available in Biosamples repository: https://www.ebi.ac.uk/biosamples/ 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Yes 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? Yes 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes 3.3.3 Have you applied a standard schema for your (meta)data? No 3.3.4 Will you provide a mapping to more commonly used ontologies? No 3.3.7 Does the described dataset / output provide qualified references with other outputs? No 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Creative Commons Attribution-NonCommercial 4.0 3.4.4 Do you intend to ensure (re)use by third parties after your project finishes? Yes 3.4.5 Is provenance well documented? Yes The sample metadata will be available in Biosamples repository: https://www.ebi.ac.uk/biosamples/ 3.4.6 What documented procedures for quality assurance do you have in place? Not available 4 Allocation of Resources 4.1 Allocation of resources 4.1.1 What will be the cost of making the described output FAIR? 0 Euro • Storage • Security Indirect cost 4.1.2 How will this cost be covered? Use of institution infrastructure 4.1.3 Identify the people who will be responsible and their role(s) in the management of the described output Marcelino Suzuki (0000-0003-3868-6362) 5 Security 5.1 Data Security 5.1.1 What security measures are followed? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 IC50 IC50 Value for the tested compound (e.g. 2.6) There are optional headers that allow you to specify the result type (integer, float, string, etc.) and unit (%, uMol, etc.) of each test result defined, but these can be entered later. RESULT_DESCR The RESULT_DESCR row lets you add an optional description for each test result to help the user better understand what it is and how it was determined. We indicate here the ID of the tested kinase. Note that certain special types are allowed such as PUBCHEM_NCBI_GENE_ID which will automatically generate links to the other database in your data table. RESULT_TYPE The second of the optional Result definition rows is the RESULT_TYPE. It lets the researchers define a type so that errors can more easily be identified and so that plotting tools can be used on the numerical parts of the data. If the type is not specified, STRING type is assumed. RESULT_UNIT The third of the optional Result definition rows is the RESULT_UNIT. It lets the researchers define a unit where appropriate. In our case, only the IC50 column had a unit. Only INTEGER and FLOAT types can have units. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.1.1.4 Do the metadata use standardised vocabularies? Yes use bioassay ontology as required by pubchem. 3.1.1.5 Please provide URL/Description of used vocabularies http://bioassayontology.org/ Kinase: An enzyme that catalyzes the transfer of a phosphate group from ATP to specific substrates, often regulating their activity. ATP (Adenosine Triphosphate): The primary energy carrier in cells, formed through processes like oxidative and substrate-level phosphorylation Protein kinases are enzymes that modify other proteins by adding phosphate groups to them, a process known as phosphorylation. This action plays a critical role in regulating various cellular processes, including cell signaling, Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 metabolism, and gene expression, making protein kinases essential components in eukaryotic translational and post-translational gene regulation. Protein kinase inhibitor: It is a type of enzyme inhibitor that can block the action of protein kinases. Primary Screening: analysis of the bioactivity by testing one or two doses of the molecule or natural extracts. IC50: The concentration of a drug, inhibitor or natural extract, needed to inhibit a biological process or response by 50%. IC50 is commonly used as a measure of drug potency. IC50 assays are also used for screening in target-based drug discovery campaigns. 3.1.1.6 Are the metadata searchable? Yes 3.1.1.7 How are searchable metadata provided? Metadata repository Accessible in the pubchem repository and/or in https://www.ebi.ac.uk/biostudies. 3.1.1.8 Are keywords provided in the metadata? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 No 3.1.1.9 Are metadata harvestable? Yes Accessible in the pubchem repository and/or https://www.ebi.ac.uk/biostudies. 3.2 Making data and other outputs openly accessible 3.2.1 Repository 3.2.1.1 In which repository will the dataset / output be deposited? PubChem PubChem is an open chemistry database at the National Institutes of Health (NIH). “Open” means that you can put your scientific data in PubChem and that others may use it. Since the launch in 2004, PubChem has become a key chemical information resource for scientists, students, and the general public. Each month our website and programmatic services provide data to several million users worldwide. PubChem mostly contains small molecules, but also larger molecules such as nucleotides, carbohydrates, lipids, peptides, and chemically-modified macromolecules. We collect information on chemical structures, identifiers, chemical and physical properties, biological activities, patents, health, safety, toxicity data, and many others. 3.2.1.2 Is the selected repository a trusted source? Yes • Has certification • Follows repository standards • Details terms of use • Has an open access content policy • Supports retention • Supports withdrawal Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 • Supports back up • Provides Open Access content (free at the point of use) • Assigns PIDs • Follows metadata standards • Uses non-proprietary formats • Supports midand long-term preservation • Follows curation processes • Supports authentication and authorization of users • Has data security mechanisms in place • Other 3.2.1.4 Add appropriate arrangements made with the repository(ies) where the described dataset will be deposited All the listed arrangements above. 3.2.1.5 Does the repository(ies) assign datasets / outputs with persistent identifiers? Yes 3.2.1.6 Does the repository(ies) resolve the identifiers to a digital object? Yes. 3.2.1.7 Does the repository support versioning? Yes 3.2.2 Data 3.2.2.1 What is the described dataset / output title? Inhibitory activity of purified compounds 3.2.2.2 How is the dataset / output shared? Closed Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Closed during the embargo time, then public access is possible via the repository Pubchem. 3.2.2.3 What is the reason of limiting access to the dataset / output? As the data can be used to find new therapeutic compounds, an embargo period of two yearsmust be applied to seek protection of the intellectual property (e.g. patents) or of the time needed for the publication of the results (approx. 6-12 months). Note here that the results can be also published as preprint articles to speed up dissemination of the non-patentable discoveries. 3.2.2.4 If an embargo applies, please specify when the dataset / output will be made available. 2029-01-01 3.2.2.5 Are there any methods or tools required to access the dataset / output? No 3.2.2.8 Is the described dataset / output supported by a data access committee? Yes A data access committee should be constituted by the leader of team who provided the fractions (chemists) or natural extracts to the screening facility and by the biologists who were able to show the bioactivity. Together they decide if the data can be shared. 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends The dataset will be submitted in pubchem and be public available after embargo time ends. is publicly available in repository, it can accessed anonymously. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.2.10 Please specify how long after the project has ended the dataset / output will be made accessible for Indefinitely. 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes Metadata information will be accessible in the repository, even during the embargo time. 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Yes Is all in the same repository. 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? No Both metadata and data will be available indefinitely in the public repository. 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes Bioassay ontology. The ID used for the identification of the targets tested is a standardized terminology available on Uniprot database: ex. GSK-3a (P49840). Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 UniProt is the world's leading high-quality, comprehensive and freely accessible resource of protein sequence and functional information. The UniProt consortium and host institutions EMBL-EBI, SIB and PIR are committed to the long-term preservation of the UniProt databases. 3.3.3 Have you applied a standard schema for your (meta)data? No 3.3.4 Will you provide a mapping to more commonly used ontologies? No We follow the rules of the bioassay ontology and pubchem. Biontology uses OWL. 3.3.6 What community-endorsed interoperability best practices are followed? Submit to a public established repository. 3.3.7 Does the described dataset / output provide qualified references with other outputs? No Yes, o.... 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? Creative Commons Attribution Share-Alike 4.0 2029-01-01 Two years for a patent and up to one year for an scientific article. 3.4.2 What reusability and / or reproducibility methods are followed? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 • Readme files • Analyses • Variable definitions • Units of measurement 3.4.3 Will you provide the described dataset / output in the public domain? Yes 3.4.4 Do you intend to ensure (re)use by third parties after your project finishes? Yes The data produced will be available upon due date of the embargo. 3.4.5 Is provenance well documented? Yes From the initial sample with biosamples ID to LIMS references IDs throughout the project pipeline. 3.4.6 What documented procedures for quality assurance do you have in place? • Data conform to format specification • Consistency verified with data models and standards Laboratory notebook. 4 Allocation of Resources 4.1 Allocation of resources 4.1.1 What will be the cost of making the described output FAIR? Approximately 5,000 € (costs for storage of data on servers during 15 years) Euro Storage Indirect cost Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 4.1.2 How will this cost be covered? Use of institution infrastructure 4.1.3 Identify the people who will be responsible and their role(s) in the management of the described output Stéphane Bach (0000-0002-7186-7483) Contact also Thomas Robert (0000-0002-1076-7251) or Blandine Baratte (0000-0002-2064-9558) 5 Security 5.1 Data Security 5.1.1 What security measures are followed? • Firewall • Passwords • Physical access control 5.1.2 What conditions do the security measures meet? • Data access • Data storage 5.1.3 How will you preserve the described dataset / output in the long term? Submission to pubchem. Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.2.5 Are there any methods or tools required to access the dataset / output? No 3.2.2.8 Is the described dataset / output supported by a data access committee? No 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends through the protocols.io website if open 3.2.2.10 Please specify how long after the project has ended the dataset / output will be made accessible for as far as we know eternally 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Yes 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? Yes 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.3.3 Have you applied a standard schema for your (meta)data? No 3.3.7 Does the described dataset / output provide qualified references with other outputs? No 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? Creative Commons Attribution-NonCommercial 4.0 2026-10-01 3.4.2 What reusability and / or reproducibility methods are followed? Other n/a 3.4.3 Will you provide the described dataset / output in the public domain? Yes 3.4.4 Do you intend to ensure (re)use by third parties after your project finishes? Yes 3.4.5 Is provenance well documented? Yes The original Biosamples ID of the samples of the dataset description "A list of biomass samples from marine Streptomyces sp. CA-237351 with production conditions" will be referenced for provenance purposes. 3.4.6 What documented procedures for quality assurance do you have in place? Other Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 4 Allocation of Resources 4.1 Allocation of resources 4.1.1 What will be the cost of making the described output FAIR? 1 Euro • Storage • Re-use • Security Indirect cost 4.1.2 How will this cost be covered? Use of institution infrastructure 4.1.3 Identify the people who will be responsible and their role(s) in the management of the described output Marcelino Suzuki (0000-0003-3868-6362) 5 Security 5.1 Data Security 5.1.1 What security measures are followed? • Passwords • Other 5.1.2 What conditions do the security measures meet? Data sharing 5.1.3 How will you preserve the described dataset / output in the long term? Publication in EUREMAP Protocols Community at protocols.io Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 6 Ethical Aspects 6.1 Ethical aspects 6.1.1 Are there any ethical or legal issues that can have an impact on sharing the described dataset / output? no 6.1.2 Does the described dataset / output contain sensitive information? No 6.1.3 Does the described dataset / output contain personal data? No 7 Other Issues 7.1 Other 7.1.1 Do you make use of other procedures for data management? No Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Chemical extraction: Green extraction and purification of both, known and novel streptocyclinones. Protocols for the extraction and chromatographic fractionation of cultures of Streptomyces sp. producing known and novel streptocyclinones. Template: Horizon Europe Type: Dataset 1 Summary 1.1 Brief description of the described research output 1.1.1 What kind of research output are you describing? Protocols 1.1.2 Is it physical or digital? Digital 1.1.3 Are you generating or re-using it? New Data will be generated from new samples obtained during the development of the project. 1.1.4 What is the type of the described dataset? Experimental Protocols will include a description of the experimental process followed for the extraction and purification of new compounds 1.1.5 What is its format? PDF files Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 1.1.6 What is its expected size? 30 Mb 1.1.7 Why are you collecting/generating or re-using it? • To share information • To keep on record To share information on procedures used for the purification of streptocyclinones To keep on record of experimental conditions and other details 1.1.8 What is its origin / provenance? Instruments used in the fractionation of extracts and lab notebooks 1.1.9 To whom might it be useful ('data utility')? • Researchers • Research communities • Industry Data might be useful to reproduce the process in the future by other researchers in an academic or industrial settings. 2 Links Between Outputs 2.1 Publications 2.1.1 Does the described output support any scientific publication? No 2.1.2 Is there a data availability statement provided along with the publication? No 2.2 Datasets 2.2.1 Does the described output use or support any published dataset? No Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 2.3 Software 2.3.1 Does the described output use or support any software? No 3 FAIR Practices 3.1 Making data and other outputs findable, including provisions for metadata 3.1.1 Making data findable, including provisions for metadata 3.1.1.1 What type(s) of persistent identifier(s) are used for the described dataset / output? • Data identifiers • Researchers identifiers DOI ORCID Once deposited, data will be available through a DOI Assigned by the database 3.1.1.2 Will you provide metadata for the described dataset / output? Yes Metadata will include origin and type of data 3.1.1.3 What type(s) of metadata? • Descriptive • Administrative 3.1.1.4 Do the metadata use standardised vocabularies? Yes 3.1.1.5 Please provide URL/Description of used vocabularies Those required by Protocols 3.1.1.6 Are the metadata searchable? Yes Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.1.1.7 How are searchable metadata provided? Metadata repository Metadata will be described in the Protocols.io (EUREMAP Protocols Community), which provides search capabilities. 3.1.1.8 Are keywords provided in the metadata? No 3.1.1.9 Are metadata harvestable? Yes 3.2 Making data and other outputs openly accessible 3.2.1 Repository 3.2.1.1 In which repository will the dataset / output be deposited? Protocols.io https://www.protocols.io/ A secure platform for developing and sharing reproducible methods. 3.2.1.4 Add appropriate arrangements made with the repository(ies) where the described dataset will be deposited Agreement to the terms of use and submission as set out by Protocols.io 3.2.1.5 Does the repository(ies) assign datasets / outputs with persistent identifiers? Yes 3.2.1.6 Does the repository(ies) resolve the identifiers to a digital object? Yes 3.2.1.7 Does the repository support versioning? Yes Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 3.2.2 Data 3.2.2.1 What is the described dataset / output title? Protocols for the extraction of microbial cultures and the fractionation of extracts 3.2.2.2 How is the dataset / output shared? Open The database is open to all researchers 3.2.2.8 Is the described dataset / output supported by a data access committee? No 3.2.2.9 Please specify how the dataset / output will be accessed during and after the project ends The dataset and associated metadata will be available (longterm) via the Protocols repository once all the IP and publication issues have been solved Through registration in Protocols 3.2.2.10 Please specify how long after the project has ended the dataset / output will be made accessible for Datasets will be available forever through Protocols 3.2.3 Metadata 3.2.3.1 Will you provide metadata even if the described dataset / output can not be openly shared? Yes Datasets will be open after an embargo period 3.2.3.2 Under which license will metadata be provided? Creative Commons Zero (CC0) 3.2.3.3 Do metadata provide information about how to access the described dataset / output? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025 Yes 3.2.3.4 Will metadata remain available after the dataset / output is no longer available? Yes Not relevant because data will be stored in a permanent repository 3.3 Making data and other outputs interoperable 3.3.1 Does your (meta)data use a controlled vocabulary? Yes The vocabulary standards required by Protocols.io 3.3.3 Have you applied a standard schema for your (meta)data? Yes Couldn't find it? Insert it manually Standard required by Protocols.io 3.3.7 Does the described dataset / output provide qualified references with other outputs? No 3.4 Increasing data and other outputs reuse 3.4.1 What internationally recognised licence will you use for your dataset / output? Creative Commons Attribution 4.0 After IP or publication issues have been solved 3.4.2 What reusability and / or reproducibility methods are followed? Other Instructions from Protocols.io 3.4.3 Will you provide the described dataset / output in the public domain? Data Management Plan | EUREMAP demonstrator project: Enhancing the Production and Therapeutic Potential of Streptocyclinones for Alzheimer’s Disease. LICENSE:CC-BYSA-4.0 DOI: - 19/11/2025